Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 1575793, 12 pages
https://doi.org/10.1155/2017/1575793
Research Article

Bufei Huoxue Capsule Attenuates PM2.5-Induced Pulmonary Inflammation in Mice

1Graduate School, Beijing University of Chinese Medicine, 11 North 3rd Ring East Road, Chaoyang District, Beijing 100029, China
2National Clinical Research Center for Respiratory Diseases and Traditional Chinese Medicine Department of Pulmonary Diseases, China-Japan Friendship Hospital, 2 Yinghua Dongjie, Hepingli, Chaoyang District, Beijing 100029, China
3Clinical Research Institute, China-Japan Friendship Hospital, 2 Yinghua Dongjie, Hepingli, Chaoyang District, Beijing 100029, China
4Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Science, 16 Dongzhimennei Nanxiaojie, Dongcheng District, Beijing 100700, China
5School of Environment, State Key Joint Laboratory of Environment Simulation and Pollution Control, Tsinghua University, Beijing 100084, China
6State Environmental Protection Key Laboratory of Sources and Control of Air Pollution Complex, Beijing 100084, China
7Geriatrics, China-Japan Friendship Hospital, 2 Yinghua Dongjie, Hepingli, Chaoyang District, Beijing 100029, China
8Zhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou City, Henan Province 450008, China

Correspondence should be addressed to Hongchun Zhang; moc.oohay@znuhcgnoh

Received 21 October 2016; Revised 4 January 2017; Accepted 29 January 2017; Published 27 February 2017

Academic Editor: Jae Youl Cho

Copyright © 2017 Yue Jing et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Atmospheric fine particulate matter 2.5 (PM 2.5) may carry many toxic substances on its surface and this may pose a public health threat. Epidemiological research indicates that cumulative ambient PM2.5 is correlated to morbidity and mortality due to pulmonary and cardiovascular diseases and cancer. Mitigating the toxic effects of PM2.5 is therefore highly desired. Bufei Huoxue (BFHX) capsules have been used in China to treat pulmonary heart disease (cor pulmonale). Thus, we assessed the effects of BFHX capsules on PM2.5-induced pulmonary inflammation and the underlying mechanisms of action. Using Polysearch and Cytoscape 3.2.1 software, pharmacological targets of BFHX capsules in atmospheric PM2.5-related respiratory disorders were predicted and found to be related to biological pathways of inflammation and immune function. In a mouse model of PM2.5-induced inflammation established with intranasal instillation of PM2.5 suspension, BFHX significantly reduced pathological response and inflammatory mediators including IL-4, IL-6, IL-10, IL-8, TNF-α, and IL-1β. BFHX also reduced keratinocyte growth factor (KGF), secretory immunoglobulin A (sIgA), and collagen fibers deposition in lung and improved lung function. Thus, BFHX reduced pathological responses induced by PM2.5, possibly via regulation of inflammatory mediators in mouse lungs.